The transfer of processed stool from a healthy donor into a recipient's gastrointestinal tract to restore a disrupted microbial community. FMT is the most direct form of microbiome intervention — replacing the entire community rather than supplementing individual strains probiotics or feeding existing commensals prebiotics. It represents community-level ecological restoration.
Mechanism
FMT introduces a complex, intact microbial ecosystem including bacteria, archaea, fungi mycobiome, bacteriophages, and their metabolites. Proposed mechanisms of action:
- Colonization resistance restoration: Donor commensals outcompete pathogens for niches and nutrients.
- SCFA production recovery: Donor butyrate/propionate producers re-establish fermentative metabolism and colonocyte energy supply.
- Bile acid metabolism normalization: Donor bacteria restore secondary bile acid production, which inhibits C. difficile sporulation.
- Immune recalibration: Restored SCFA and indoles production rebalances Treg/Th17 and reduces inflammation.
- Barrier repair: Recovered butyrate production strengthens tight junctions and restores hypoxic colonic environment.
Clinical Evidence by Disease
C. difficile Infection (Gold Standard)
- FMT cures recurrent C. difficile in ~90% of cases — far superior to antibiotics alone.
- FDA-approved live biotherapeutic products (REBYOTA, VOWST) now available.
- Mechanism primarily through restored colonization resistance and secondary bile acid metabolism.
IBD (Mixed Results)
- Ulcerative colitis: Multiple RCTs show induction of remission in 25-35% of patients (vs. 5-10% placebo), but durability and optimal protocols remain uncertain.
- Crohn's disease: Preliminary evidence; timing of repeat FMT may be critical (e.g., second FMT within 3 weeks showed greater mucosal improvement).
- Challenge: IBD involves immune dysregulation beyond what microbiome restoration alone can correct.
Multiple Sclerosis (Pilot Data)
- Mouse models: FMT from MS-twin-derived microbiota increased autoimmune incidence; FMT from healthy donors showed protective immunoregulatory activity [1].
- Sutterella reduction identified as a key change in MS-associated FMT.
- Human data remain very limited; larger trials needed.
Cardiovascular Disease / Hypertension
- FMT from atherosclerotic mice induces atherosclerosis in recipient mice, demonstrating causal microbial contribution [2].
- FMT as an innovative therapeutic approach for managing CVD is under active investigation [3].
Autism Spectrum Disorder (Open-Label)
- Open-label FMT trial in ASD children reduced levels of p-cresol, 4-hydroxyphenylacetate, and indole; modified Prevotella, bifidobacterium, and Desulfovibrio abundances [4].
- GI symptoms and behavioral measures improved; effects persisted at 2-year follow-up in extended observations.
- Controlled trials are needed to confirm efficacy.
Other Applications Under Investigation
- Metabolic syndrome/obesity: FMT from lean donors to obese recipients temporarily improved insulin sensitivity in some trials.
- Hepatic encephalopathy: FMT reduced hospitalizations in cirrhotic patients.
- Graft-versus-host disease: FMT showing promise for steroid-refractory GI GVHD.
Metal Angle
FMT may restore the metal-handling capacity of the microbiome disrupted by heavy metal exposure:
- Biosorption capacity: Healthy donor microbiota includes metal-binding species (Lactobacillus, Bifidobacterium) that sequester Pb, Cd, and Hg in the gut lumen.
- Barrier repair: Restored SCFA production reduces paracellular metal absorption through healed tight junctions.
- Competitive exclusion: Donor commensals displace metal-tolerant pathobionts (Enterobacteriaceae) that thrive in metal-contaminated, inflamed environments.
- Detoxification enzymes: Donor bacteria may contribute arsenic methyltransferases (arsM), mercury demethylases (merB), and other biotransformation enzymes.
Limitations and Risks
- Donor screening: Risk of transmitting infections, antibiotic-resistant organisms, or unfavorable metabolic phenotypes.
- Durability: Engraftment is often incomplete; recipient diet and environment may select against donor species.
- Standardization: No consensus on preparation (fresh vs. frozen, capsule vs. colonoscopy), dosing, or donor selection criteria.
- Regulatory: Classified as a biological product; access varies by jurisdiction.
See Also
- probiotics — single/multi-strain supplementation approach
- prebiotics — substrate-based microbiome modulation
- dysbiosis — the target condition FMT aims to correct
- butyrate — key metabolite restored by successful FMT